Literature DB >> 29255240

Bladder cancer: Multi-omic profiling refines the molecular view.

Carolyn D Hurst1, Margaret A Knowles1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29255240     DOI: 10.1038/nrclinonc.2017.195

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.

Authors:  Steven A Roberts; Michael S Lawrence; Leszek J Klimczak; Sara A Grimm; David Fargo; Petar Stojanov; Adam Kiezun; Gregory V Kryukov; Scott L Carter; Gordon Saksena; Shawn Harris; Ruchir R Shah; Michael A Resnick; Gad Getz; Dmitry A Gordenin
Journal:  Nat Genet       Date:  2013-07-14       Impact factor: 38.330

2.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

3.  Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Authors:  Roland Seiler; Hussam Al Deen Ashab; Nicholas Erho; Bas W G van Rhijn; Brian Winters; James Douglas; Kim E Van Kessel; Elisabeth E Fransen van de Putte; Matthew Sommerlad; Natalie Q Wang; Voleak Choeurng; Ewan A Gibb; Beatrix Palmer-Aronsten; Lucia L Lam; Christine Buerki; Elai Davicioni; Gottfrid Sjödahl; Jordan Kardos; Katherine A Hoadley; Seth P Lerner; David J McConkey; Woonyoung Choi; William Y Kim; Bernhard Kiss; George N Thalmann; Tilman Todenhöfer; Simon J Crabb; Scott North; Ellen C Zwarthoff; Joost L Boormans; Jonathan Wright; Marc Dall'Era; Michiel S van der Heijden; Peter C Black
Journal:  Eur Urol       Date:  2017-04-05       Impact factor: 20.096

4.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Authors:  Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

5.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

6.  Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis.

Authors:  Firas Abdollah; Giorgio Gandaglia; Rodolphe Thuret; Jan Schmitges; Zhe Tian; Claudio Jeldres; Niccolò Maria Passoni; Alberto Briganti; Shahrokh F Shariat; Paul Perrotte; Francesco Montorsi; Pierre I Karakiewicz; Maxine Sun
Journal:  Cancer Epidemiol       Date:  2013-02-26       Impact factor: 2.984

7.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Authors:  A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

8.  Discovery and saturation analysis of cancer genes across 21 tumour types.

Authors:  Michael S Lawrence; Petar Stojanov; Craig H Mermel; James T Robinson; Levi A Garraway; Todd R Golub; Matthew Meyerson; Stacey B Gabriel; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2014-01-05       Impact factor: 49.962

9.  Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.

Authors:  Gottfrid Sjödahl; Pontus Eriksson; Fredrik Liedberg; Mattias Höglund
Journal:  J Pathol       Date:  2017-03-28       Impact factor: 7.996

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

  10 in total
  9 in total

1.  The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer.

Authors:  Danijel Sikic; Helge Taubert; Johannes Breyer; Markus Eckstein; Veronika Weyerer; Bastian Keck; Jennifer Kubon; Wolfgang Otto; Thomas S Worst; Maximilian C Kriegmair; Philipp Erben; Arndt Hartmann; Bernd Wullich; Ralph M Wirtz; Sven Wach
Journal:  Cancer Manag Res       Date:  2021-08-20       Impact factor: 3.989

Review 2.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

3.  Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.

Authors:  Yinjie Su; Weiping Yang; Ning Jiang; Juanyi Shi; Luping Chen; Guangzheng Zhong; Junming Bi; Wei Dong; Qiong Wang; Chunhui Wang; Tianxin Lin
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

4.  MicroRNAs Which Can Prognosticate Aggressiveness of Bladder Cancer.

Authors:  Edyta Marta Borkowska; Tomasz Konecki; Michał Pietrusiński; Maciej Borowiec; Zbigniew Jabłonowski
Journal:  Cancers (Basel)       Date:  2019-10-14       Impact factor: 6.639

5.  Long noncoding RNAs to predict postoperative recurrence in bladder cancer and to develop a new molecular classification system.

Authors:  Zhiyong Li; Lijuan Jiang; Zhiling Zhang; Minhua Deng; Wensu Wei; Huancheng Tang; Shengjie Guo; Yunlin Ye; Kai Yao; Zhuowei Liu; Fangjian Zhou
Journal:  Cancer Med       Date:  2021-11-24       Impact factor: 4.452

6.  Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis.

Authors:  Wenlong Zhang; Xin He; Haoli Yin; Wenmin Cao; Tingsheng Lin; Wei Chen; Wenli Diao; Meng Ding; Hao Hu; Wenjing Mo; Qing Zhang; Hongqian Guo
Journal:  J Hematol Oncol       Date:  2022-07-14       Impact factor: 23.168

7.  Patient attrition in Molecular Tumour Boards: a systematic review.

Authors:  Hannah Frost; Donna M Graham; Louise Carter; Paul O'Regan; Dónal Landers; André Freitas
Journal:  Br J Cancer       Date:  2022-08-08       Impact factor: 9.075

Review 8.  Bladder Cancer: New Insights into Its Molecular Pathology.

Authors:  Kentaro Inamura
Journal:  Cancers (Basel)       Date:  2018-04-01       Impact factor: 6.639

Review 9.  Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.

Authors:  Milena Matuszczak; Maciej Salagierski
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.